ACHV — Achieve Life Sciences Balance Sheet
0.000.00%
- $81.86m
- $57.33m
Annual balance sheet for Achieve Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 35.9 | 43 | 24.8 | 15.5 | 34.4 |
Net Total Receivables | — | 0.153 | 0.105 | 0.111 | — |
Prepaid Expenses | |||||
Total Current Assets | 37 | 44.6 | 27.3 | 17 | 36.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.188 | 0.079 | 0.127 | 0.079 | 0.127 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 40.3 | 47.5 | 30 | 19.4 | 38.6 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.94 | 4.55 | 21.6 | 20.8 | 6.68 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 3.01 | 19.5 | 21.7 | 20.8 | 17.7 |
Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 37.3 | 28 | 8.3 | -1.45 | 20.9 |
Total Liabilities & Shareholders' Equity | 40.3 | 47.5 | 30 | 19.4 | 38.6 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |